[1] Blackstone C. Cellular pathways of hereditary spastic paraplegia. Annu Rev Neurosci. 2012;35:25- 47.
[2] Blackstone C. Hereditary spastic paraplegia. Handb Clin Neurol. 2018;148:633-652.
[3] Fink JK. Hereditary spastic paraplegia: clinical principles and genetic advances. Semin Neurol. 2014;34:293-305.
[4] Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: from SPG1 to SPG72 and still counting. Rev Neurol. 2015;171:505-530.
[5] Tesson C, Koht Jeanette, Stevanin G. Delving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosology. Hum Genet. 2015;134:511-538.
[6] Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014;261:518-539.
[7] Fink JK. Hereditary spastic paraplegia: clinic-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126:307-328.
[8] Saputra L, Kumar KR. Challenges and controversies in the genetic diagnosis of hereditary spastic paraplegia. Curr Neurol Neurodci Rep. 2021;21:15.
[9] Harding A.E. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1:1151-1155.
[10] Guelly C, Zhu PP, Leonardis L, Papić L, Zidar J et al. Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. Am J Hum Genet. 2011;88:99-105.
[11] Beetz C, Pieber TR, Hertel N, Schabhüttl M, Fischer C et al. Exome sequencing identifies a REEP1 mutation involved in distal hereditary motor neuropathy type V. Am J Hum Genet. 2012;91:133-145.
[12] 内海裕也，湯浅⿓彦，遺伝性痙性対⿇痺の概念と分類．Brain and Nerve. 2003;55:739-747.
[13] Harding AE. Hereditary "pure" spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry. 1981;44:871-883.
[14] Jouet M, Rosenthal A, Armstrong G, MacFarlane J, Stevenson R et al. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet. 1994;7:402-407.
[15] Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014; 42:174-183.
[16] Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain. 2009;132:1577- 1588.
[17] Coutinho P, Ruano L, Loureiro JL, Cruz VT, Barros J et al. Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. JAMA Neurol. 2013;70:746-755.
[18] 瀧⼭嘉久，遺伝性痙性対⿇痺の最新情報．臨床神経．2014;54:1009-1011.
[19] Hazan J, Fonknechten N, Mavel D, Paternotte C, Samson D et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. 1999;23:296- 303.
[20] Lan MY, Chang YY, Yeh TH, Lai SC, Liou CW et al. High frequency of SPG4 in Taiwanese families with autosomal dominant hereditary spastic paraplegia. BMC Neurol. 2014;14:216.
[21] H Shimazaki. Clinical aspects of hereditary spastic paraplegias. Clin Neurol. 2014;54:1012-1015.
[22] Beetz C, Nygren AO, Schickel J, Auer-Grumbach M, Bürk K et al. High frequency of partial SPAST deletions in autosomal dominant hereditary spastic paraplegia. Neurology. 2006;67:1926-1930.
[23] Joanna M. Solowska, Peter W. Baas. Hereditary spastic paraplegia SPG4: what is known and not known about the disease. Brain. 2015;138:2471-2484.
[24] Boone PM, Yuan B, Campbell IM, Scull JC, Withers MA et al. The Alu-rich genomic architecture of SPAST predisposes to diverse and functionally distinct disease-associated CNV alleles. Am J Hum Genet. 2014;95:143-161.
[25] Kadnikova VA, Rudenskaya GE, Stepanova AA, Sermyagina IG, Ryzhkova OP. Mutational spectrum of Spast (Spg4) and Atl (Spg3a) genes in Russian patients with hereditary spastic paraplegia. Sci Rep. 2019;9:14412.
[26] O'Donnell JP, Byrnes LJ, Cooley RB, Sondermann H. A hereditary spastic paraplegia-associated atlastin variant exhibits defective allosteric coupling in the catalytic core. J Biol Chem. 2018;293:687- 700.
[27] Tom Strachan, Andrew Read. ヒトの分⼦遺伝学第 4 版．(2011)
[28] Boukhris A, Stevanin G, Feki I, Denora P, Elleuch N et al. Tunisian hered- itary spastic paraplegias: clinical variability supported by genetic heterogeneity. Clin Genet. 2009;75:527–536.
[29] Erichsen AK, Koht J, Stray-Pedersen A Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain. 2009;132:1577– 1588.
[30] Martin E, Schüle R, Smets K, Rastetter A, Boukhris A et al. Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am J Hum Genet. 2013;92:238–244.
[31] Southgate L. Dafou D, Hoyle J, Li N, Kinning E et al. Novel SPG11 mutations in Asian kindreds and disruption of spatacsin func- tion in the zebrafish. Neurogenetics. 2010;11:379–389.
[32] Murmu RP, Martin E, Rastetter A, Esteves T, Muriel MP et al. Cellular distribution and subcellular localization of spatacsin and spastizin, two proteins involved in hereditary spastic paraplegia. Mol Cell Neurosci. 2011;47:191-202.
[33] Khundadze M, Kollmann K, Koch N, Biskup C, Nietzsche S et al. A hereditary spastic paraplegia mouse model supports a role of ZFYVE26/SPASTIZIN for the endolysosomal system. PloS Genet. 2013;9:e1003988.
[34] Vantaggiato C, Panzeri E, Castelli M, Citterio A, Arnoldi A et al. ZFYVE26/SPASTIZIN and SPG11/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis. Autophagy. 2019;15:34-57.
[35] Hanein S, Martin E, Boukhris A, Byrne P, Goizet C et al. Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet. 2008;82:992-1002.
[36] Stevanin G. Spastic Paraplegia 11. GeneReviews[Internet]. 2008
[37] Guidubaldi A, Piano C, Santorelli FM, Silvestri G, Petracca M et al. Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism. Mov Disord. 2011;26:553-556.
[38] Starling A, Rocco P, Cambi F, Hobson GM, Passos Bueno MR et al. Further evidence for a fourth gene causing X-linked pure spastic paraplegia. Am J Med Genet. 2002;111:152-156.
[39] Estey CM. Congenital hydrocephalus. Vet Clin North Am Small Anim Pract. 2016;46:217-219.
[40] Kahle KT, Kulkarni AV, Limbrick DD Jr, Warf BC. Hydrocephalus in children. Lancet. 2016;387:788-799.
[41] Sagan L. On the origin of mitosing cells. T Theor Biol. 1967;14:255-274.
[42] Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet. 1990;46:428-433.
[43] Ganetzky RD, Stendel C, McCormick EM, Zolkipli-Cunningham Z, Goldstein AC et al. MT- ATP6 mitochondrial disease variants: Phenotypic and biochemical features analysis in 218 published cases and cohort of 14 new cases. Hum Mutat. 2019;40:499-515.
[44] Verny C, Guegen N, Desquiret V, Chevrollier A, Prundean A et al. Hereditary spastic paraplegia- like disorder due to a mitochondrial ATP6 gene point mutation. Mitochondrion. 2011;11:70-75.
[45] Garret P, Bris C, Procaccio V, Amati-Bonneau P, Vabres P et al. Deciphering exome sequencing data: Bringing mitochondrial DNA variants to light. Hum Mutat. 2019;40:2430-2443.
[46] Takiyama Y. [Hereditary spastic paraplegia in Japan]. Rinsho Shinkeigaku. 2011;51:1125-1128.
[47] Takiyama Y. [Japan Spastic Paraplegia Research Consortium (JASPAC)]. Brain Nerve. 2014;66:1210-1217.
[48] H, Noda K, Toyama T, Iwasaki N, Iwaki A, Ayabe M, Aizawa H, Taniwaki T, Fukumaki Y. Partial SPAST and DPY30 deletions in a Japanese spastic paraplegia type 4 family. Neurogenetics. 2011; 12: 25-31.
[49] Morikawa T, Miura S, Tateishi T, Noda K, Shibata H. A Japanese hereditary spastic paraplegia family with a rare nonsynonymous variant in the SPAST gene. Hum Genome Var. 2021;8:21.
[50] Liu L, Li Y, Li S, Hu N, He Y et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol. 2012;251364.
[51] Slatko BE, Gardner AF, Ausubel FM. Overview of Next-generation sequencing technologies. Curr Protoc Mol Biol. 2018;122:e59.
[52] Ross JP, Dion PA, Rouleau GA. Exome sequencing in genetic disease: recent advances and considerations. F10000Res. 9:F1000 Facility Rev-336.
[53] Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to trandlation. Nat Rev Genet. 2013;14:681-691.
[54] Kelemen O, Convertini P, Zhang Z, Wen Yuan, Shen M et al. Function of alternative splicing. Gene. 2013;514:1-30.
[55] Petersen BS, Fredrich B, Hoeppner MP, Ellinghaus D, Franke A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet. 2017;18:14.
[56] Majewsk J, Schwartzentruber J, Lalonde E, Montpetit A. Jabado N. What can exome sequencing do for you? J Med Genet. 2011;48:580-589.
[57] Bioinformatics analysis of whole exome sequencing data. Methods Mol Biol. 2019;1881:277-318.
[58] Vaz-Drago R, Custódio N, Carmo-Fonseca M. Deep intronic mutations and human disease. Hum Genet. 2017;136:1093-1111.
[59] Paulson H. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105-123.
[60] Macé A, Kutalik Z, Valsesia A. Copy number variation. Methods Mol Biol. 2018;1793:231-258.
[61] Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:1122-1130.
[62] The 1000 Genomes Project Consortium. A map of human genome variation from population- scale sequencing. Nature. 2010;467:1061-1073.
[63] The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56-65.
[64] Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285-291.
[65] Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J et al. Genome Aggregation Database Consortium, Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434-443.
[66] Danjoh I, Saito S, Sato Y, Mimori T, Tsuda K et al. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. Nat Commun. 2015;6:8018.
[67] 国⽴⼤学法⼈東北⼤学東北メディカル・メガバンク機構プレスリリース，⽇本⼈ 3,554⼈分の全ゲノムリファレンスパネルを作成．2017 年．
[68] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-249.
[69] Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7.20.
[70] Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812-3814.
[71] Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC. SIFT missense predictions for genomes. Nat Protocol. 2016; 11:1-9.
[72] Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310-315.
[73] Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2018;47:D886-D894.
[74] Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice-improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Med. 2021;13:31.
[75] Bangham CR, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers. 2015. 18;1:15012.
[76] 井樋栄⼆，吉川秀樹，津村弘，⽥中栄，⾼⽊理彰．標準整形外科学第 14 版．医学書院．(2020)
[77] ⽔野美邦．標準神経病理学第 2 版．医学書院． (2012)
[78] Acharya AB, Jamil RT, Dewey JJ. Babinski Reflex. StatPearls [Internet]. 2020.
[79] Wu C, Fan D. A novel missense mutation of the DDHD1 gene associated with juvenile amyotropic lateral sclerosis. Front Aging Neurosci. 2016;8:291.
[80] Tesson C, Nawara M, Salih MA, Rossignol R, Zaki MS et al. Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and functional in hereditary spastic paraplegia. Am J Hum Genet. 2012;91:1051-1064.
[81] Liguori R, Giannoccaro MP, Arnoldi A, Citterio A, Tonon C et al. Impairment of brain and muscle energy metabolism detected by magnetic resonance spectroscopy in hereditary spastic paraparesis type 28 patients with DDHD1 mutations. J Neurol. 2014;261:1789-1793.
[82] Higgs HN, Han MH, Johnson GE, Glomset JA. Cloning of a phosphatidic acid-preferring phospholipase A1 from bovine testis. J Bio Chem. 1998;273:5468-5477.
[83] Inoue H, Baba T, Sato S, Ohtsuki R, Takemori A et al. Roles of SAM and DDHD domains in mammalian intracellular phospholipase A1 KIAA0725p. Biochim Biophys Acta. 2012;1823:930-939.
[84] Henry N, Higgs and John A. Glomset. Identification of a phosphatidic acid-preffereing phosopholipase A1 from bovine brain and testis. Proc Natl Acid Sci U S A. 1994;91:9574-9578.
[85] S Lev. The role of the Nir/rdgB protein family in membrane trafficking and cytoskeleton remodeling. Exp Cell Res. 2004;297:1-10.
[86] Baba T, Kashiwagi Y, Arimitsu N, Kogure T, Edo A et al. Phosphatidic acid (PA)-preferring phospholipase A1 regulates mitochondrial dynamics. J Biol Chem. 2014;289:11497-11511.
[87] Yamashita A, Kamazawa T, Koga H, Suzuki N, Oka S et al. Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1. Biochim Biophys Acta. 2010;1801:711-20.
[88] Kurosaki T, Maquat LE. Nonsense-mediated mRNA decay in humans at a glance. J Cell Sci. 2016;129:461-467.
[89] Sakakibara Y, Irie T, Suzuki Y, Yamashita R, Wakaguri H et al. Intrinsic promoter activities of primary DNA sequences in the human genome. DNA Res. 2007;14-71-77.
[90] Brown JC. Involvement of promoter/enhancers in a feedback loop to regulate human gene expression. Heliyon. 2020;6:e0934.
[91] Miller JN, Pearce DA. Nonsense-mediated decay in genetic disease: friend or foe? Mutat Res Rev Mutat Res. 2014;762:52-64.
[92] Bouslam N, Benomar A, Azzedine H, Bouhouche A, Namekawa M et al. Mapping of a new form of pure autosomal recessive spastic paraplegia (SPG28). Ann Neurol. 2005;57:567-571.
[93] Boutry M, Morais S, Stevanin G. Update on the genetics of spastic paraplegias. Curr Neurol Neurosci Rep. 2019;19:18.
[94] Hall B, Limaye A, Kulkarni AB. Overview: generation of gene knockout mice. Curr Protoc Cell Biol. 2009;19.12:1-17.
[95] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154-156.
[96] Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature. 1985;317:230-234.
[97] Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-deriver stem cells. Cell. 1987;51:503-512
[98] Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. 1996;93:1156-1160.
[99] Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nuclease. Genetics. 2002;161:1169-1175.
[100] Boch J, Scholze H, Schornack S, Landgraf A, Hahn S et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326:1509-1512.
[101] Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F et al. Targeting DNA double-strand breaks with TAL effector nuclease. Genetics. 2010;186:757-761.
[102] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-821.
[103] Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the ipa gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429-5433.
[104] Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. A putative RNA-interference- based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct. 2006;1-7.
[105] Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709-1712.
[106] Horvath, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010;327:167-170.
[107] Wiedenheft B, Sternberg SH, Doudna JA. ENA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482:331-338.
[108] ⽯野良純．発⾒者が語る 奇妙なくり返し配列，それが CRISPR だった！．実験医学2015 年 6 ⽉号 Vol.33 No.9.
[109] Bennett EP, Petersen BL, Johansen IE, Niu Y, Yang Z et al. INDEL detection, the 'Achilles heel' of precise genome editing: a survey of methods for accurate profiling of gene editing induced indels. Nucleic Acid Res. 2020;48:11958-11981.
[110] Mignarri A, Rubegni A, Tessa A, Stefanucci S, Malandrini A et al. Mitochondrial dysfunction in hereditary spastic paraparesis with mutations in DDHD1/SPG28. J Neurol Sci. 2016;362:287-291.
[111] Dard R, Meyniel C, Touitou V, Stevanin G, Lamari F et al. Mutations in DDHD1, encording a phospholipase A1, is a novel cause of retinopathy and neurodegenerarion with brain iron accumulation. Euro J Med Genet. 2017;60:639-642.
[112] Aloulou A, Rahier R, Arhab Y, Noiriel A, Abousalham A. Phospholipases: An Overview. Methods Mol Biol. 2018;1835:69-105.
[113] Aloulou A, Ali YB, Bezzine S, Gargouri Y, Gelb MH. Phospholipases: An overview. Methods Mol Biol. 2012;861:63-85.
[114] Richmond GS Smith TK. Phospholipase A1. Int J Mol Sci. 2011;12:588-612.
[115] Tani K, Kogure T, Inoue H. The intracellular phospholipase A1 protein family. Biomol Concepts. 2012;3:471-478.
[116] Inoue A, Aoki J. Phospholipase A1, structure, distribution and function. Future Lipidol. 2006;1:623-636.
[117] Higgs H, N Glomset JA, Purification and properties of a phosphatidic acid- preferring phospholipase A1 from bovine testis. J Biol Chem. 1996;271:10874–10883.
[118] Tani K, Mizoguchi T, Iwamatsu A, Hatsuzawa K, Tagaya M. p125 is a novel mammalian Sec23p- interacting protein with structural similarity to phospholipid-modifying proteins. J Biol Chem. 1999;274:20505–20512.
[119] Nakajima K, Sonoda H, Mizoguchi T, Aoki J, Arai H et al. A novel phospholipase A1 with sequence homology to a mammalian Sec23p-interacting protein, p125. J Biol Chem. 2002;277:11329– 11335.
[120] Mizoguchi T, Nakajima K, Hatsuzawa K, Nagahama M, Hauri HP et al. Determination of functional regions of p125, a novel mammalian Sec23p-interacting protein. Biochem Biophys Res Commun. 2000;279:144-149.
[121] Shimoi W, Ezawa I, Nakamoto K, Uesaki S, Gabreski G et al. p125 is localized in endoplasmic reticulum exit sites and involved in their organization. J Biol Chem. 2005;280:10141-10148.
[122] Inloes JM, Jing H, Cravatt B. The spastic paraplegia-associated phospholipase DDHD1 is a primery brain phosphatidylinositol lipase. Biochemistry. 2018;57:5759-5767.
[123] Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas- mediated genome engineering. Nat protoc. 2015;9:1956-1968.
[124] Qiu P, Shandilya H, D'Alessio JM, O'Connor K, Durocher J et al. Mutation detection using Surveyor nuclease. Biotechniques. 2004;36:702-707
[125] Beetz C, Koch N, Khundadze M, Zimmer G, Nietzsche S et al. A spastic paraplegia mouse model reveals REEP1-dependent ER shaping. J Clin Invest. 2013;123,4273-4282.
[126] Silva JM, McMahon Martin. The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp. 2014;5:e51149.
[127] Takeda H, Izumi Y, Takahashi M, Paxton T, Tamura S et al. Widely-targeted quantitative lipidomics method by supercritical fluid chromatography triple quadrupole mass spectrometry. J Lipid Res. 2018;59:1283-1293.
[128] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser. 1995;B57:289-300.
[129] Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
[130] Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105-1111.
[131] Ghosh S, Chan CK. Analysis of RNA-Seq data using TopHat and Cufflinks. Methods Mol Biol. 2016;1374:339-361.
[132] Trapnell C, Roberts A, Goff L, Pertea G, Kim D et al. Differental gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562-578.
[133] Huang DW, Sherman BT, Tan Q, Kir J, Liu D et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35:W169-175.
[134] Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2007;9:a018309.
[135] Kovacs GG. Cellular reactions of the central nervous system. Handb Clin Neurol. 2017;145:13- 23.
[136] Pekny M, Wilhelmsson U, Bogestål YR, Pekna M. The role of astrocytes and complement system in neural plasticity. Int Rev Neurobiol. 2007;82:95-111.
[137] Pekny M, Wilhelmsson U, Pekna M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett. 2014;565:30-38.
[138] Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature. 2002;417:941-4.
[139] Dutta S, Sengupta P. Men and mice: relating their ages. Life Science. 2016;152:244-248.
[140] Irintchev A, Simova O, Eberhardt KA, Morellini F, Schachner M. Impacts of lesion severity and tyrosine kinase receptor B deficiency on functional outcome of femoral nerve injury assessed by a novel single-frame motion analysis in mice. Eur J Neurosci. 2005;22:802-808.
[141] J. Goizet C, Boukhris A, Maltete D, Guyant-Maréchal L, Truchetto J et al. SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. Neurology. 2009;73:1111-1119.
[142] Ebrahimi-Fakhari D, Alecu JE, Blackstone C. Spastic Paraplegia 15. GeneReviews [Internet], 2021
[143] Sun YM Lu C, Wu ZY. Spinocerebellar ataxia: relationship between phenotype and genotype – a review. Clinical Genet. 2006;90:305-314.
[144] Liu J, Tang TS, Tu H, Nelson O, Herndon E et al. Deranged calucium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci. 2009;29:9148-9162.
[145] Guy AT, Kamiguchi H. Lipids as new players in axon guidance and circuit development. Curr Opin Neurobiol. 2021;66:22-29.
[146] Cherif H, Argaw A, Cécyre B, Bouchard A, Gagnon J, et al. Role of GPR55 during Axon Growth and Target Innervation. eNeuro. 2015;2(5):e0011-15.
[147] Balenga NA, Aflaki E, Kargl J, Platzer W, Schröder R et al. GPR55 regulates cannabinoid 2 receptor-mediated response in human neutrophils. Cell. Res. 2011;21(10):1452-69.
[148] Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther. 2010;126(3):301-13.
[149] Ross RA. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci. 2011;32(5):265-9.
[150] Obara Y, Ueno S, Yanagihata Y, Nakahata N. Lysophosphatidylinositol causes neurite reaction via GPR55, G13 and RhoA in PC12 cells. PLoS One. 2011;6(8):e24284.
[151] Govek EE, Wu Z, Acehan D, Molina H, Rivera K et al. Cdc42 Regulates Neuronal Polarity during Cerebellar Axon Formation and Glial-Guided Migration. iScience. 2018;1:35-48.
[152] Imai F, Ladle DR, Leslie JR, Duan X, Rizvi TA et al. Synapse Formation in Monosynaptic Sensory–Motor Connections Is Regulated by Presynaptic Rho GTPase Cdc42. J Neurosci. 2016; 36:5724-35.
[153] Dupraz S, Hilton BJ, Husch A, Santos TE, Coles CH et al. RhoA controls axon extension independent of specification in the developing brain. Curr Biol. 2019;29:3874-86.e.9.
[154] Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun. 2007;362:928-934.
[155] Brown AJ, Robin Hiley C. Is GPR55 an anandamide receptor? Vitam Horm. 2009;81:111-37.
[156] Yang H, Zhou J, Lehmann C. GPR55 – a putative “type 3” cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27:297-302.
[157] Ryberg E, Larsson N, Sjögren NL, Hjorth S, Hermansson N-O et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092-1101.
[158] Zaoui K, Duhamel S. Colorimetric RhoB GTPase activity assay. Bio Protoc. 2020;10:e3609.
[159] Thomas RA, Gibon J, Chen CXQ, Chierzi S, Soubannier VG et al. The nogo receptor ligand LGl1 regulates synapse number and synaptic activity in hippocampal and cortical neurons. eNeuro. 2018;5:ENEURO.0185-18.
[160] Pitcher JA. Freedman NJ, Lefkowitz RJ et al. G protein-coupled receptor kinases. Annu Rev Biochem. 1998;67:653-692.
[161] Rajagopal S, Shenoy SK. GPCR desensitization: Acute and prolonged phases. Cell Signal. 2018;41:9-16.
[162] Lohse MJ, Engelhardt S, Danner S, Böhm M. Mechanisms of beta-adrenergic receptor desensitization: from molecular biology to heart failure. Basic Res Cardiol. 1996;91Suppl2:29-34
[163] Pype JL, Mak JC, Dupont LJ, Verleden GM, Barnes PJ. Desensitization of the histamine H1- receptor and transcriptional down-regulation of histamine H1-receptor gene expression in bovine tracheal smooth muscle. Br J Pharmacol. 1998;125:1477-1484.
[164] Mundell S, Kelly E. Adenosine receptor desensitization and trafficking. Biochim Biophys Acta. 2011;1808:1319-1328.
[165] He D, Lasek AW. Anaplastic Lymphoma Kinase Regulates Internalization of the Dopamine D2 Receptor. Mol Pharmacol. 2020;97:123-131.
[166] Barton AC, Sibley DR. Agonist-induced desensitization of D1-dopamine receptors linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells. Mol Pharmacol. 1990;38:531-541.
[167] Oliveira-Giacomelli Á, Naaldijk Y, Sardá-Arroyo L, Gonçalves MCB, Corrêa-Velloso J et al. Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. Front Pharmacol. 2018;9:325.
[168] Lingor P, Koch JC, Tönges L, Bähr M. Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res. 2012;349:289-311.
[169] Salvadores N, Sanhueza M, Manque P, Court FA. Axonal degeneration during aging and its functional role in neurodegenerative disorders. Front Neurosci. 2017;11:451.
[170] Doi H, Ushiyama M, Baba T, Tani K, Shiina M et al. Late-onset spastic ataxia phenotype in a patient with a homozygous DDHD2 mutation. Sci Rep. 2014;4:7132.
[171] Gonzalez M, Nampoothiri S, Kornblum C, Oteyza AC, Walter J et al. Mutations in phospholipase DDHD2 cause autosomal recessive hereditary spastic paraplegia (SPG54). Eur J Hum Genet. 2013;21:1214-1218.
[172] Schuurs-Hoeijmakers JH, Geraghty MT, Kamsteeg EJ, Ben-Salem S, de Bot ST et al. Mutations in DDHD2, encoding an intracellular phospholipase A(1), cause a recessive form of complex hereditary spastic paraplegia. Am J Hum Genet. 2012;91:1073-1081.
[173] Maruyama T, Baba T, Maemoto Y, Hara-Miya、chi C, Hasegawa-Ogawa M et al. Loss of DDHD2, whose mutation causes spastic paraplegia, promotes reactive oxygen species generation and apoptosis. Cell Death Dis. 2018;9:797.
[174] Carter RJ, Morton J, Dunnett SB. Motor coordination and balance in rodents. Curr Protpc Neurosci. 2001;Chapter 8:Unit 8.12.
[175] Luong TN, Carlisle HJ, Southwell A, Patterson PH. Assessment of motor balance and coordination in mice using the balance beam. J Vis Exp. 2011;2376.
[176] Aronson JK, Ferner RE. Biomarkers-A general review. Curr Protoc Pharmacol. 2017;76:9.23- 1-9.23.17.
[177] Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44:2963-2997.
[178] Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019;16:93-103.
[179] Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat. 2007;28:831- 845.
[180] Blau N. Genetics of Phenylketonuria: Then and Now Hum Mutat. 2016;37:508-515.
[181] Fernández-Cañón JM, Granadino B, Beltrán-Valero de Bernabé D, Renedo M, Fernández-Ruiz E et al. The molecular basis of alkaptonuria. Nat Genet. 1996;14:19-24.
[182] Sharabi AF, Goudar R. Alkaptonuriaq. StatPearls [Internet]. 2021.
[183] Berguig GY, Martin NT, Creer AY, Xie L, Zhang L et al. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain. Mol Genet Metab. 2019;128:422- 430.
[184] Preston AJ, Keenan CM, Sutherland H, Wilson PJ, Wlodarski B. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis. 2014;73:284-289.
[185] McDermott MI, Wang Y, Wakelam MJO, Bankaitis VA. Mammalian phospholipase D: function, and therapeutics. Prog Lipid Res. 2020;78:101018.
[186] Zachowski A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J. 1993;294:1-14.
[187] 榎本和⽣，リン脂質分⼦の膜動態と細胞⾻格制御．⽣化学．2008;80:811-819.
[188] Li YY, Zhang WC, Zhang JL, Zheng CJ, Zhu H et al. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis. Lipids Health Dis. 2015;14:72.
[189] Sedláková I, Vávrová J, Tošner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol. 2011;32:311-316.
[190] Xu Y, Shen Z, Wiper DW, Wu M, Morton RE et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719-723.
[191] Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277:48737-48744.
[192] Ninou I, Magkrioti C, Aidinis V. Autotaxin in pathophysiology and pulmonary fibrosis. Front Med (Lausanne). 2018;5:180.
[193] 清⽔嘉⽂，徳村彰．リゾホスファチジン酸の⽣理学的役割および疾患との関連．⽣化学．2011;83:506-517.
[194] Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007;41:616-623.
[195] Magkrioti C, Galaris A, Kanellopoulou P, Stylianaki EA, Kaffe E et al. Autotaxin and chronic inflammatory diseases. J Autoimmun. 2019;104:102327.
[196] Liu S, Murph M, Panupinthu N, Mills GB. ATX-LPA receptor axis in inflammation and cancer. Cell cycle. 2009;8:3695-3701.
論文の公開元へ
